Roche?s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe
- Reduces infusion time to 2 hours from the conventional 3.5 hours for patients with relapsing or primary progressive multiple sclerosis
- EMA approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional OCREVUS dosing regimen
Attachment